Nasdaq · CIK 0001390478
SLS SELLAS Life Sciences Group, Inc.
Insider trading from SEC Form 4. Last filing Jun 18, 2026. Close $11.65 on Oct 9, 2026, +738% from the 52-week low and -25% from the high.
SELLAS Life Sciences Group, Inc. (SLS) has 21 SEC Form 4 filings on file from 8 insiders, the latest filed on Jun 18, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 open-market trades have been scored at SLS. The newest: Katherine Bach Kalin (director) bought $101k of stock on Nov 19, 2025, filed Nov 21, 2025, scored 35 (weak). 2 insiders bought within 14 days of each other around Jun 12, 2025.
SLS closed at $11.65 on Oct 9, 2026, 738% above its 52-week low and 25% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at SELLAS Life Sciences Group, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | Katherine Bach Kalin director buy | $101k 63,400 shares | +155% | - | |
| 33Weak | Robert L Van Nostrand director buy | $15k 10,000 shares | +96% | - | |
| 46Moderate | Jane Wasman director buy | $34k 20,000 shares | +192% | - | |
| 39Weak | Katherine Bach Kalin director buy | $36k 20,000 shares | +95% | - |
Transactions
Every row filed, 26 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Angelos M. Stergiou President and CEO | AGrant or award Common Stock | +1,065,000 | $0.00 | $0 | 1,759,183 | Jun 18, 2026 |
| Jan 7, 2026 | John Thomas Burns CFO | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 554,327 | Jan 9, 2026 |
| Jan 7, 2026 | Dragan Cicic SVP, Chief Development Officer | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 557,805 | Jan 9, 2026 |
| Jan 7, 2026 | Katherine Bach Kalin director | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 154,400 | Jan 9, 2026 |
| Jan 7, 2026 | David A Scheinberg director | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 73,082 | Jan 9, 2026 |
| Jan 7, 2026 | Jane Wasman director | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 92,900 | Jan 9, 2026 |
| Jan 7, 2026 | Robert L Van Nostrand director | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 82,900 | Jan 9, 2026 |
| Jan 7, 2026 | John Varian director | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 72,900 | Jan 9, 2026 |
| Dec 3, 2025 | John Thomas Burns CFO | JOther Common Stock | -58,592 | $1.50 | $88k | 254,327 | Dec 5, 2025 |
| Dec 3, 2025 | Dragan Cicic SVP, Chief Development Officer | JOther Common Stock | -63,800 | $1.50 | $96k | 257,805 | Dec 5, 2025 |
| Dec 3, 2025 | Angelos M. Stergiou President and CEO | JOther Common Stock | -187,066 | $1.50 | $281k | 686,966 | Dec 5, 2025 |
| Nov 19, 2025 | Katherine Bach Kalin director | POpen-market purchase Common Stock | +63,400 | $1.59 | $101k | 104,400 | Nov 21, 2025 |
| Jun 12, 2025 | Robert L Van Nostrand director | POpen-market purchase Common Stock | +10,000 | $1.48 | $15k | 20,400 | Jun 13, 2025 |
| May 30, 2025 | Jane Wasman director | POpen-market purchase Common Stock | +20,000 | $1.69 | $34k | 30,400 | Jun 2, 2025 |
| May 22, 2025 | Katherine Bach Kalin director | POpen-market purchase Common Stock | +20,000 | $1.80 | $36k | 41,000 | May 22, 2025 |
| Jan 10, 2025 | John Thomas Burns CFO | AGrant or award Common Stock | +113,000 | $0.00 | $0 | 217,762 | Jan 14, 2025 |
| Jan 10, 2025 | Dragan Cicic SVP, Chief Development Officer | AGrant or award Common Stock | +113,000 | $0.00 | $0 | 228,328 | Jan 14, 2025 |
| Jan 10, 2025 | Katherine Bach Kalin director | AGrant or award Common Stock | +12,500 | $0.00 | $0 | 21,000 | Jan 14, 2025 |
| Jan 10, 2025 | John Thomas Burns CFO | AGrant or award Common Stock | +81,300 | $0.00 | $0 | 299,062 | Jan 14, 2025 |
| Jan 10, 2025 | Dragan Cicic SVP, Chief Development Officer | AGrant or award Common Stock | +81,300 | $0.00 | $0 | 309,628 | Jan 14, 2025 |
| Jan 10, 2025 | Katherine Bach Kalin director | AGrant or award Stock Option (Right to Buy)derivative | +18,500 | $0.00 | $0 | 18,500 | Jan 14, 2025 |
| Jan 10, 2025 | John Thomas Burns CFO | AGrant or award Stock Option (Right to Buy)derivative | +169,500 | $0.00 | $0 | 169,500 | Jan 14, 2025 |
| Jan 10, 2025 | Dragan Cicic SVP, Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +169,500 | $0.00 | $0 | 169,500 | Jan 14, 2025 |
| Dec 4, 2024 | John Thomas Burns CFO | JOther Common Stock | -7,165 | $1.13 | $8,096 | 104,762 | Dec 5, 2024 |
| Dec 4, 2024 | Dragan Cicic SVP, Chief Development Officer | JOther Common Stock | -8,256 | $1.13 | $9,329 | 115,328 | Dec 5, 2024 |
| Dec 4, 2024 | Angelos M. Stergiou President and CEO | JOther Common Stock | -28,289 | $1.13 | $32k | 358,132 | Dec 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- John Thomas BurnsCFO
- Dragan CicicSVP, Chief Development Officer
- Katherine Bach Kalindirector
- David A Scheinbergdirector
- Angelos M. StergiouPresident and CEO
- Robert L Van Nostranddirector
- John Variandirector
- Jane Wasmandirector
Questions about SLS
Answered from the filings on this page, as of the latest one.
Are insiders buying SLS?
No. In the last 90 days no insider at SELLAS Life Sciences Group, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade SLS on the open market?
Katherine Bach Kalin (director) bought $101k of SLS on Nov 19, 2025 and filed the Form 4 on Nov 21, 2025. InsiderTell scored 35 (weak).
How many insiders file Form 4 at SELLAS Life Sciences Group, Inc.?
8 people have filed a Form 4 at SELLAS Life Sciences Group, Inc., among them John Thomas Burns (CFO), Dragan Cicic (SVP, Chief Development Officer), Katherine Bach Kalin (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.